A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib
Nom du journal : Eur J Cancer
Année : 2020
Volume : 126
Page de départ : 45
Page de fin : 55